Reportedly, Johnson & Johnson (JNJ) has appointed Thibaut Mongon as the chief executive officer of the consumer health division, the division which the pharmaceutical giant plans to spin off into a listed company by the end of next year. Mongon joined the company in 2000, and currently serves as the executive vice president and worldwide chairman of the company’s consumer health division. In November, J&J announced it would spin off its consumer health division that sells Listerine and Baby Powder and focus on pharmaceuticals and medical devices. The transition would happen after the separation completes, that is expected to happen within 2023, subject to legal requirements.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
